Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab vedotin + rituximab bridging before tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma
ACTRN12626000586314Phase 2Not yet recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of polatuzumab vedotin, rituximab and tisagenlecleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Complete remission at 3 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
polatuzumab vedotinrituximabtisagenlecleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ACTRN12626000586314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000586314.